Arrayit Corporation (ARYC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Arrayit Corporation (ARYC) trades at $0.00 with AI Score 58/100 (Grade B). Arrayit Corporation develops and markets life science tools and integrated systems for genetic analysis and diagnostics. Market cap: $7,935, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for ARYC: ARYC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ARYC against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ARYC: 1/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Arrayit Corporation (ARYC) Healthcare & Pipeline Overview
Arrayit Corporation develops, manufactures, and markets life science tools and integrated systems for genetic variation analysis and diagnostics. The company's microarray technology and instruments serve genomic research centers, pharmaceutical companies, and academic institutions. With a focus on early disease detection, Arrayit operates in the competitive medical diagnostics and research sector.
What Is the Investment Thesis for ARYC?
Arrayit Corporation operates in the medical diagnostics and research sector, focusing on microarray technology. The company's gross margin of 49.4% indicates potential profitability in its core operations. However, the negative profit margin of -231.4% raises concerns about overall financial health. Key growth catalysts include expanding the application of its microarray technology in early disease detection and increasing sales of automated microarray instruments. Potential risks include the company's small market capitalization of 8K and high beta of -15.67, indicating high volatility. Investors should carefully consider the financial metrics and market position before investing.
Based on FMP financials and quantitative analysis
ARYC Key Highlights
- Gross margin of 49.4% suggests potential efficiency in Arrayit's core microarray technology business.
- Negative profit margin of -231.4% raises concerns about the company's overall financial health and expense management.
- Market capitalization of 8K indicates the company is a micro-cap stock with associated volatility and liquidity risks.
- Beta of -15.67 suggests the stock price moves inversely and with greater magnitude than the market, indicating high volatility.
- Arrayit serves genomic research centers, pharmaceutical companies, and academic institutions, indicating a diversified customer base within the life sciences sector.
Who Are ARYC's Competitors?
ARYC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| BDSX Biodesix, Inc. | $21.85 | -0.64% | $177.87M | 58 |
| ILMN Illumina, Inc. | $192.56 | +2.06% | $29.13B | 58 |
| OLK Olink Holding AB (publ) | $26.08 | +0.31% | $3.24B | 58 |
| DIUXF Diaceutics PLC | $2.00 | +0.00% | $169.26M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ARYC's Key Strengths?
- Proprietary microarray printing technology
- Integrated systems for genetic variation analysis
- Established relationships with research institutions
- Specialized expertise in microarray applications
What Are ARYC's Weaknesses?
- Negative profit margin
- Small market capitalization
- High beta indicating high volatility
- Limited financial resources
What Could Drive ARYC Stock Higher?
- Expansion of microarray applications in early disease detection.
- Increasing sales of automated microarray instruments.
- Development and marketing of consumables for microarray technology.
- Entering strategic partnerships with pharmaceutical companies.
- Expanding into international markets.
What Are the Key Risks for ARYC?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger companies with greater resources.
- Regulatory changes affecting the medical diagnostics industry.
- Technological advancements rendering current products obsolete.
- Economic downturns impacting research funding.
- Negative profit margin and limited financial resources.
What Are the Growth Opportunities for ARYC?
- Expanding Microarray Applications in Early Disease Detection: Arrayit can capitalize on the growing demand for early disease detection by developing and marketing diagnostic microarrays for various treatable disease states. The market for early disease diagnostics is projected to reach billions of dollars by 2030, driven by advancements in genomics and proteomics. Arrayit's microarray technology offers a platform for high-throughput screening and personalized medicine, providing a competitive advantage in this expanding market. Timeline: Ongoing.
- Increasing Sales of Automated Microarray Instruments: Arrayit can increase revenue by expanding the sales of its automated microarray manufacturing instruments, such as NanoPrint and SpotBot Titan, to research institutions and pharmaceutical companies. The market for automated laboratory equipment is expected to grow, driven by the need for increased efficiency and throughput in research and development. Arrayit's instruments offer customizable solutions for microarray manufacturing, catering to the specific needs of its customers. Timeline: Ongoing.
- Developing and Marketing Consumables for Microarray Technology: Arrayit can leverage its existing customer base by developing and marketing consumables, such as glass substrates, reagents, and clean room supplies, for microarray technology. The market for laboratory consumables is stable and recurring, providing a consistent revenue stream for the company. By offering high-quality consumables specifically designed for its instruments, Arrayit can enhance customer loyalty and increase market share. Timeline: Ongoing.
- Entering Strategic Partnerships with Pharmaceutical Companies: Arrayit can accelerate its growth by entering strategic partnerships with pharmaceutical companies to develop and commercialize diagnostic microarrays and tools for specific disease areas. Collaborating with established pharmaceutical companies can provide access to funding, expertise, and distribution channels, enabling Arrayit to expand its market reach and product portfolio. These partnerships can focus on developing personalized medicine solutions and companion diagnostics. Timeline: Ongoing.
- Expanding into International Markets: Arrayit can expand its geographic reach by targeting international markets, particularly in Asia and Europe, where there is growing demand for life science tools and diagnostic technologies. Entering new markets requires adapting products and services to local regulatory requirements and customer needs. By establishing partnerships with local distributors and research institutions, Arrayit can effectively penetrate these markets and increase its global presence. Timeline: Ongoing.
What Opportunities Does ARYC Have?
- Expanding microarray applications in early disease detection
- Increasing sales of automated microarray instruments
- Developing and marketing consumables
- Entering strategic partnerships with pharmaceutical companies
What Threats Does ARYC Face?
- Competition from larger companies
- Regulatory changes
- Technological advancements
- Economic downturns
What Are ARYC's Competitive Advantages?
- Proprietary microarray printing technology.
- Integrated systems for genetic variation analysis.
- Established relationships with research institutions and pharmaceutical companies.
- Specialized expertise in microarray technology and applications.
What Does ARYC Do?
Arrayit Corporation, founded to advance life science research and diagnostics, develops, manufactures, and markets tools and integrated systems for analyzing genetic variation and biological function. The company's core business revolves around microarray technology, which enables the analysis of DNA, protein, antibody, lipid, and carbohydrate microarrays for applications such as gene expression, genotyping, and protein profiling. Arrayit offers a range of automated microarray manufacturing instruments, including the NanoPrint, SpotBot Titan, and SpotLight CCD fluorescence scanners. These instruments cater to various research and diagnostic needs, providing solutions for high-throughput sample processing and analysis. In addition to instruments, Arrayit manufactures consumables like glass substrates, reagents, and clean room supplies. The company serves genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies worldwide. Headquartered in Sunnyvale, California, Arrayit Corporation continues to focus on developing innovative tools for early disease detection and advancing life science research.
What Products and Services Does ARYC Offer?
- Develops microarray tools and components.
- Manufactures life science tools and integrated systems.
- Markets life science tools and integrated systems.
- Offers custom printing and analysis of microarrays for research.
- Identifies and develops diagnostic microarrays for early disease detection.
- Provides automated microarray manufacturing instruments.
How Does ARYC Make Money?
- Sales of microarray tools and components to research institutions and pharmaceutical companies.
- Custom printing and analysis of microarrays for research purposes.
- Development and sales of diagnostic microarrays for early disease detection.
- Manufacturing and sales of automated microarray manufacturing instruments.
What Industry Does ARYC Operate In?
Arrayit Corporation operates within the medical diagnostics and research industry, a sector characterized by rapid technological advancements and increasing demand for personalized medicine. The market for microarray technology is driven by the need for high-throughput analysis of genetic variation and biological function. Arrayit competes with companies offering similar tools and services, including those specializing in genomics, proteomics, and diagnostics. The industry is subject to regulatory requirements and intellectual property protection, influencing the competitive landscape and market access.
Who Are ARYC's Key Customers?
- Genomic research centers
- Pharmaceutical companies
- Academic institutions
- Clinical research organizations
- Government agencies
- Biotechnology companies
How Arrayit Corporation Is Valued
Arrayit Corporation carries a market capitalization of 8K, placing it in the micro-cap category. Relative to its peer group, ARYC's quantitative score of 58/100 is roughly in line with the peer average of 65/100.
Company Profile
Arrayit Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Sunnyvale, US. The company is led by CEO Rene A. Schena. ARYC has traded publicly since 2001.
ROE 55%Key Financial Metrics
Return on equity for Arrayit Corporation stands at 54.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.10 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
Arrayit Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ARYC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary microarray printing technology
- Integrated systems for genetic variation analysis
- Established relationships with research institutions
- Specialized expertise in microarray applications
Bear Case
- Negative profit margin
- Small market capitalization
- High beta indicating high volatility
- Limited financial resources
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ARYC Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
ARYC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARYC.
Price Targets
Wall Street price target analysis for ARYC.
ARYC MoonshotScore
What does this score mean?
The MoonshotScore rates ARYC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Rene A. Schena
Managing
Rene A. Schena is the managing person at Arrayit Corporation, overseeing the company's operations and strategic direction. Information about his detailed career history, education, and previous roles is not available in the provided data. He is responsible for leading the company's efforts in developing, manufacturing, and marketing life science tools and integrated systems.
Track Record: Due to limited information, Rene A. Schena's specific achievements, strategic decisions, and company milestones under his leadership cannot be comprehensively assessed. However, as the managing person, he is responsible for guiding the company's activities in the competitive life sciences technology sector and managing its seven employees.
ARYC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Arrayit Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like NYSE or NASDAQ due to the lack of stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Monitor news and press releases for any updates or developments.
- Consult with a financial advisor before investing.
- Development of microarray tools and components.
- Manufacturing of life science tools and integrated systems.
- Marketing of life science tools and integrated systems.
What Investors Ask About Arrayit Corporation (ARYC) — Healthcare
What does Arrayit Corporation do?
Arrayit Corporation develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics. The company's core offerings include microarray printing technology, automated microarray manufacturing instruments, and related consumables. Arrayit serves genomic research centers, pharmaceutical companies, academic institutions, and other organizations involved in life science research and diagnostics, providing tools for gene expression analysis, genotyping, and protein profiling.
What do analysts say about ARYC stock?
There is currently no available analyst coverage or consensus on Arrayit Corporation (ARYC) due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before considering an investment in ARYC. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, may not be readily available or reliable due to limited financial disclosure and trading activity.
What are the main risks for ARYC?
The main risks for Arrayit Corporation include its negative profit margin, small market capitalization, and high beta, indicating high volatility. As an OTC-listed company, ARYC faces additional risks related to limited financial disclosure, low trading volume, and potential for price manipulation. Competition from larger companies with greater resources and regulatory changes in the medical diagnostics industry also pose significant challenges. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for ARYC?
Arrayit Corporation (ARYC) holds an AI score of 58/100 (moderate). Not financial advice.
How frequently does ARYC data refresh on this page?
ARYC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ARYC's recent stock price performance?
Arrayit Corporation (ARYC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary microarray printing technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ARYC overvalued or undervalued right now?
Valuing Arrayit Corporation (ARYC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ARYC?
Before investing in Arrayit Corporation (ARYC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be limited due to OTC listing.
- AI analysis pending for ARYC.